These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34503215)

  • 21. Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
    Ji Y; Wang Q; Zhao Q; Zhao S; Li L; Sun G; Ye L
    Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9557-9568. PubMed ID: 31686145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
    Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma.
    Ursu S; Majid S; Garger C; de Semir D; Bezrookove V; Desprez PY; McAllister S; Soroceanu L; Nosrati M; Yimam K; Hassoun A; Osorio R; Kashani-Sabet M; Dar AA
    Oncogenesis; 2019 Aug; 8(8):42. PubMed ID: 31409772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.
    Garcia PL; Miller AL; Gamblin TL; Council LN; Christein JD; Arnoletti JP; Heslin MJ; Reddy S; Richardson JH; Cui X; van Waardenburg RCAM; Bradner JE; Yang ES; Yoon KJ
    Mol Cancer Ther; 2018 Jan; 17(1):107-118. PubMed ID: 29142067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    Nizialek E; Antonarakis ES
    Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progesterone Enhances Niraparib Efficacy in Ovarian Cancer by Promoting Palmitoleic-Acid-Mediated Ferroptosis.
    Wu N; Zhang X; Fang C; Zhu M; Wang Z; Jian L; Tan W; Wang Y; Li H; Xu X; Zhou Y; Chu TY; Wang J; Liao Q
    Research (Wash D C); 2024; 7():0371. PubMed ID: 38798714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
    Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
    Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
    Fehling SC; Miller AL; Garcia PL; Vance RB; Yoon KJ
    Cancer Lett; 2020 Jan; 468():48-58. PubMed ID: 31605774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.
    Hou D; Xu G; Zhang C; Li B; Qin J; Hao X; Liu Q; Zhang X; Liu J; Wei J; Gong Y; Liu Z; Shao C
    Cell Death Dis; 2017 Oct; 8(10):e3070. PubMed ID: 28981112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proton and photon radiosensitization effects of niraparib, a PARP-1/-2 inhibitor, on human head and neck cancer cells.
    Wang L; Cao J; Wang X; Lin E; Wang Z; Li Y; Li Y; Chen M; Wang X; Jiang B; Zhang R; Sahoo N; Zhang X; Zhu XR; Myers JN; Frank SJ
    Head Neck; 2020 Sep; 42(9):2244-2256. PubMed ID: 32323895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niraparib for the treatment of metastatic ccRCC in a patient with
    Yue X; Yang C; Cao D; Li Y
    Front Pharmacol; 2024; 15():1396606. PubMed ID: 38953104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
    Weigert V; Jost T; Hecht M; Knippertz I; Heinzerling L; Fietkau R; Distel LV
    BMC Cancer; 2020 Aug; 20(1):775. PubMed ID: 32811446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
    Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
    Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein.
    Nebenzahl-Sharon K; Sharf R; Amer J; Shalata H; Khoury-Haddad H; Sohn SY; Ayoub N; Hearing P; Kleinberger T
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31315986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.